Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Remember to take our free assessment quiz to connect with our network of providers and begin your personalized treatment plan
ARADES trial: A first-in-man, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
The weight-loss and diabetes drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, are not inhibitors
US$ 27.66
US$ 25.81
US$ 24.33
.png)
US$ 29.56
US$ 29.23
US$ 20.53
US$ 25.76
